HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Augusto D’Onofrio Stefano Auriemma Paolo Magagna Antonio Cannarella Massimo Bilotta Nicola Abbiate Nicola Lamascese Alessandro Fabbri Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by D’Onofrio, A. Articles by Fabbri, A. Search for Related Content PubMed PubMed Citation Articles by D’Onofrio, A. Articles by Fabbri, A.

J Thorac Cardiovasc Surg 2007;134:491-495
© 2007 The American Association for Thoracic Surgery

Surgery for Acquired Cardiovascular Surgery

Aortic valve replacement with the Sorin Pericarbon Freedom stentless prosthesis: 7 years’ experience in 130 patients

Division of Cardiac Surgery, San Bortolo Hospital, Vicenza, Italy.

Received for publication February 14, 2007; revisions received March 21, 2007; accepted for publication April 11, 2007.

^_* Address for reprints: Augusto D’Onofrio, MD, Division of Cardiac Surgery, San Bortolo Hospital Viale Rodolfi 37, 36100 Vicenza, Italy. (Email: adonofrio{at}hotmail.it; adonofrio{at}cardiochirurgiaitalia.it).

Objectives: Aortic stentless pericardial valves were introduced into clinical practice to combine properties of both stentless and pericardial prostheses. The aim of this single-center retrospective study was to assess midterm clinical and hemodynamic results of aortic valve replacement with the Sorin Pericarbon Freedom stentless bioprosthesis.

Methods: From July 1999 through November 2005, 130 consecutive patients (73 [56.1%] male patients) underwent aortic valve replacement with the Sorin Pericarbon Freedom bioprosthesis at our institution. Mean age was 76 ± 5 years (range, 42-86 years), and associated procedures were performed in 50 (38.4%) patients; of these, 41 were coronary artery bypass grafts. Surgical intervention under urgent/emergency conditions and reoperations were performed in 18 (13.8%) and 7 (5.3%) patients, respectively. Mean crossclamp and cardiopulmonary bypass times were 82 ± 24 and 125 ± 40 minutes, respectively. All patients underwent clinical and echocardiographic follow-up (100% complete), and the total cumulative follow-up was 324 patient/years (mean, 2.5 ± 1.8; range, 6 months–7 years).

Results: Overall hospital mortality was 8.4%. Overall patient survival was 63% ± 6% and 50% ± 10% at 5 and 7 years, respectively. Late deaths occurred in 23 patients, and 6 of them were valve related (1.8% patient/years). Freedom from valve-related death and reoperation was 91% ± 4% and 94% ± 4%, respectively, at 7 years. No structural valve deterioration was observed. Endocarditis, thromboembolism, and hemorrhagic complications occurred in 2 (0.6% patient/years), 1 (0.3% patient/years), and 1 (0.3% patient/years) patients, respectively. Mean transprosthetic gradients for valve sizes 23, 25, and 27 were 12.1 ± 3.8, 10.8 ± 3.8, and 9 ± 3.1 mm Hg, respectively.

Conclusions: The Sorin Pericarbon Freedom stentless bioprosthesis provides good early and midterm results in terms of hemodynamic performance, survival, and freedom from valve-related complications.